Lartruvo

Active Ingredient(s): Olaratumab
FDA Approved: * October 19, 2016
Pharm Company: * ELI LILLY AND CO
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Lartruvo Overview

Olaratumab (trade name Lartruvo) is a monoclonal antibody developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.[1] It will be removed from the US and the European markets in the first half of 2019 due to insufficient proof of its medical advantage (see below "Medical uses"). Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of acti...

Read more Lartruvo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Olaratumab

Recent Lartruvo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Lartruvo: (2 results)

Sorted by National Drug Code

• 0002-7190 Lartruvo 10 mg/ml Intravenous Injection, Solution by Eli Lilly and Company
• 0002-8926 Lartruvo 10 mg/ml Intravenous Solution by Eli Lilly and Company

Other drugs which contain Olaratumab or a similar ingredient: (1 result)

• OLARATUMAB